Inactive Instrument

News GlaxoSmithKline plc London S.E.

Stocks

Pharmaceuticals

End-of-day quote London S.E. Other stock markets
- ^GBX	-

06-25	Cooler PCE, Hotter Chips
06-25	Bernstein: GSK Poised for Sustainable Growth Amid 'Much More Durable' HIV Franchise; Price Target, Forecasts Up	MT

All News

Mentions Relevance

06-25	Bernstein: GSK Poised for Sustainable Growth Amid 'Much More Durable' HIV Franchise; Price Target, Forecasts Up	MT
06-24	GSK Unit Launches Tender Offer for Nuvalent Acquisition	MT
06-24	GSK Kicks Off Tender Offer to Buy Cancer Therapies Company Nuvalent	MT
06-24	GSK launches tender offer for USD10.6 billion purchase of Nuvalent	AN
06-24	GSK : announces commencement of tender offer to acquire Nuvalent, Inc.	PU
06-23	GSK executives, including non-exec chair, buy shares	AN
06-17	GSK says US FDA approves urinary tract infection treatment Utebzi	AN
06-17	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	BU
06-17	GSK Secures US FDA Nod for Complicated Urinary Tract Infection Antibiotic	MT
06-17	GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections	MT
06-17	GSK : Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	PU
06-17	US FDA approves GSK's oral antibiotic for drug-resistant UTIs	RE
06-16	GSK's Exdensur Wins Canadian Approval for Severe Asthma, Nasal Polyps	MT
06-16	Saudi Chemical Co. Secures New Medical Marketing Services Deal from GSK Unit	MT
06-15	GSK slips despite positive analysis from UBS
06-15	GSK : UBS remains Neutral	ZD
06-12	GSK's Clonal Myeloid Disorder Treatment Gets Orphan Drug Designation From US, European Regulators	MT
06-12	GSK drug momelotinib gains regulatory nods as VEXAS treatment	AN
06-12	GSK's Momelotinib Receives US, EU Orphan Drug Designations for Vexas Syndrome	MT
06-11	Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal	RE
06-10	Intron Health Upgrades GSK to Hold Rating, Lifts PT	MT
06-10	GSK : Deutsche Bank reiterates its Neutral rating	ZD
06-10	GSK : UBS sticks Neutral	ZD
06-09	British Shares Fall Back Amid Renewed Peace Talks; GSK to Buy Nuvalent	MT
06-09	GSK : JP Morgan maintains a Sell rating	ZD